FDA Meeting on Germline Mitochondrial Replacement Postponed
Posted by Jessica Cussins October 22, 2013
Biopolitical Times
The FDA public meeting that was scheduled to take place on October 22 and 23 to discuss mitochondrial replacement, a form of human inheritable genetic modification, was postponed due to the government shutdown.
The meeting has not yet been rescheduled, and FDA staff aren’t able to say when a new date will be announced. They have said that there will also be a new deadline for submitting written comments.
The postponement has an important silver lining: there is now more time to spread the word and get involved. To learn more about the germline mitochondrial replacement techniques being discussed by regulatory authorities both in the United States and the United Kingdom, please see these resources:
- CGS’s letter to the FDA
- CGS’s jam-packed resource page on the science / ethics / media of mitochondrial replacement
- The Biopolitical Times blog posts below
Previously on Biopolitical Times: